Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'research area dna damage topoisomerase ii'

Search results for: 'research area dna damage topoisomerase ii'

Items 51-60 of 78

Page
per page
  1. GlyH-101
    B1087 GlyH-101
    Target: CFTR
    Summary: CFTR Inhibitor II
      insoluble in H2O; insoluble in EtOH; ≥20.35 mg/mL
  2. FT-207 (NSC 148958)
    B1474 FT-207 (NSC 148958)
    Summary: DNA/RNA synthesis inhibitor
      ≥100 mg/mL
  3. Mizoribine
    B1472 Mizoribine
    Target: Synthases/Synthetases
    Summary: DNA/RNA synthesis inhibitor
      insoluble in EtOH; ≥88.2 mg/mL
  4. Autocamtide-2-related inhibitory peptide
    B6831 Autocamtide-2-related inhibitory peptide
    Target: Ca2 /calmodulin-dependent protein kinases (CaMKs)
    Summary: inhibitor of calmodulin-dependent protein kinase II (CaM-kinase II, CaMKII)
      ≥40.2 mg/mL
  5. Niclosamide
    B2283 Niclosamide
    Target: STAT
    Summary: Inhibitor of the STAT3 signaling pathway
  6. VSV-G Peptide
    A6009 VSV-G Peptide
    Summary: Peptide sequence-YTDIEMNRLGK
      ≥134 mg/mL
  7. BMS 309403
    B7794 BMS 309403
     2 Citation
    Target: Fatty-acid-binding proteins (FABPs)
    Summary: FABP4 inhibitor,potent and selective
      insoluble in H2O; ≥18.15 mg/mL
  8. Cidofovir
    A5790 Cidofovir
    Target: CMV
    Summary: Anti-CMV drug;inhibitor of viral DNA syntheis
      insoluble in EtOH; insoluble in DMSO; ≥13.95 mg/mL
  9. LY2801653
    A3573 LY2801653
    Target: MET
    Summary: MET inhibitor
      ≥27.65 mg/mL
  10. NSC 74859
    A8338 NSC 74859
     5 Citation
    Target: STAT
    Summary: Stat3 inhibitor
      insoluble in H2O; ≥18.25 mg/mL

Items 51-60 of 78

Page
per page
Shop By
Now Shopping by
  1. Specificity Selective Remove This Item
Clear All
Shopping Options
Category
  1. Signaling Pathways 73item
  2. Natural Products 1 item
  3. Peptides 1 item
  4. Peptides & Proteins 1 item
Reversibility
  1. Reversible 5item
  2. Irreversible 1 item
Target
  1. Caspases 1 item
  2. Cyclin-Dependent Kinases 1 item
  3. Cathepsins 1 item
  4. Histone Deacetylases (HDACs) 2item
  5. Akt 1 item
  6. PI3K 4item
  7. mTOR 3item
  8. AP-1 1 item
  9. Myosin II ATPases 1 item
  10. Chk 2item
  11. Eph Receptors 1 item
  12. Thymidylate Synthase 1 item
  13. Pim 2item
  14. Voltage-gated Sodium (NaV) Channels 1 item
  15. PP1 1 item
  16. PP2A 1 item
  17. MET 1 item
  18. Trk Receptors 1 item
  19. STAT 3item
  20. ROCK 1 item
  21. JAK 1 item
  22. DNA-PK 5item
  23. Angiotensin AT2 Receptors 3item
  24. CFTR 1 item
  25. Topoisomerases 9item
  26. DNA Methyltransferases 3item
  27. Calpains 1 item
  28. Ubiquitin-specific proteases 1 item
  29. Ca2 /calmodulin-dependent protein kinases (CaMKs) 5item
  30. USP 1 item
  31. 5-HT2 Receptors 1 item
  32. D1 and D5 Receptors 1 item
  33. D2 Receptors 1 item
  34. D3 Receptors 1 item
  35. 5-HT1 Receptors 1 item
  36. 5-HT7 Receptors 1 item
  37. Fatty-acid-binding proteins (FABPs) 1 item
  38. ATM/ATR 2item
  39. CK2 1 item
  40. HIPK2 1 item
  41. HIPK3 1 item
  42. HIV Integrases 1 item
  43. P2X Receptors 1 item
  44. Carbonic Anhydrases 1 item
  45. BLM 1 item
  46. HSV 1 item
  47. Synthases/Synthetases 2item
  48. MAGL 1 item
  49. RNA Polymerases 1 item
  50. CMV 1 item
  51. Angiotensin AT1 Receptors 2item
  52. O6-methylguanine-DNA-methyl-transferase (MGMT) 1 item
  53. Cytidine deaminases 1 item
  54. PP4 1 item
  55. Dipeptidyl-peptidase II 1 item
  56. HCV polymerase 1 item
  57. ATM 1 item
  58. Sirtuin 1 item
Reported Experiments
  1. Animal Experiments 69item
  2. Cell Experiments 48item
Related Disease
  1. Acute Myelogenous Leukemia 2item
  2. Acute Myeloid Leukemia 2item
  3. Acute Renal Failure 1 item
  4. Adrenocortical Carcinoma 1 item
  5. Bladder Cancer 2item
  6. Bladder Carcinoma 2item
  7. Bladder Diseases 1 item
  8. Breast Cancer 12item
  9. Cancer 48item
  10. Cervical Cancer 2item
  11. Cholangiocarcinoma 1 item
  12. Colon Cancer 9item
  13. Colorectal Cancer 5item
  14. Diabetes 1 item
  15. Glioblastoma 4item
  16. Glioma 1 item
  17. Hepatitis C 1 item
  18. Hepatocellular Carcinoma 2item
  19. HIV Infections 1 item
  20. Inflammatory Diseases 2item
  21. Leukemia 4item
  22. Lung Cancer 4item
  23. Lymphoma 5item
  24. Melanoma 5item
  25. Multiple Myeloma 2item
  26. Myeloma 2item
  27. Neuroblastoma 1 item
  28. Non-small Cell Lung Carcinoma 1 item
  29. Ovarian Cancer 8item
  30. Pancreatic Cancer 5item
  31. Prostate Cancer 6item
  32. Renal Cell Carcinoma 1 item
  33. Sarcoma 1 item
  34. Schizophrenia 1 item
  35. Squamous Cell Carcinoma 1 item
  36. Testicular Cancer 2item
  37. Type 2 Diabetes 2item